ROS1 - ROS proto-oncogene 1, receptor tyrosine kinase Gene
Species: Felis catus
Gene Type: protein coding
Gene ID: 101093437
ROS1 Products (12)
| mRNA | Protein | Name |
|---|---|---|
| XM_045057952.1 | XP_044913887.1 | proto-oncogene tyrosine-protein kinase ROS isoform X6 |
| XM_045057946.1 | XP_044913881.1 | proto-oncogene tyrosine-protein kinase ROS isoform X1 |
| XM_045057950.1 | XP_044913885.1 | proto-oncogene tyrosine-protein kinase ROS isoform X4 |
| XM_045057948.1 | XP_044913883.1 | proto-oncogene tyrosine-protein kinase ROS isoform X2 |
| XM_045057951.1 | XP_044913886.1 | proto-oncogene tyrosine-protein kinase ROS isoform X5 |
| XM_045057949.1 | XP_044913884.1 | proto-oncogene tyrosine-protein kinase ROS isoform X3 |
| XM_045057951.1 | XP_044913886.1 | proto-oncogene tyrosine-protein kinase ROS isoform X5 |
| XM_045057948.1 | XP_044913883.1 | proto-oncogene tyrosine-protein kinase ROS isoform X2 |
| XM_045057946.1 | XP_044913881.1 | proto-oncogene tyrosine-protein kinase ROS isoform X1 |
| XM_045057950.1 | XP_044913885.1 | proto-oncogene tyrosine-protein kinase ROS isoform X4 |
| XM_045057949.1 | XP_044913884.1 | proto-oncogene tyrosine-protein kinase ROS isoform X3 |
| XM_045057952.1 | XP_044913887.1 | proto-oncogene tyrosine-protein kinase ROS isoform X6 |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
proto-oncogene tyrosine-protein kinase ROS |
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(9)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-50878 | Crizotinib | Inhibitor | 99.97% | Yes |
| HY-12215 | Lorlatinib | 99.99% | Yes | |
| HY-W015913 | Pyruvic acid sodium | Inhibitor | 99.86% | Yes |
| HY-12678 | Entrectinib | 99.26% | Yes | |
| HY-103022 | Repotrectinib | Inhibitor | 99.95% | Unkown |
| HY-50878A | Crizotinib hydrochloride | 99.86% | Yes | |
| HY-145574 | Iruplinalkib | Inhibitor | 99.62% | Unkown |
| HY-12215R | Lorlatinib (Standard) | 99.92% | Unkown | |
| HY-50878B | Crizotinib acetate | Inhibitor | / | Unkown |
Clinical Phase
Bioactive Molecules
(7)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-131003A | Taletrectinib free base | Inhibitor | / | Phase 3 |
| HY-176942 | JYP0322 | Inhibitor | / | Phase 3 |
| HY-131003 | Taletrectinib | Inhibitor | 99.63% | Phase 2 |
| HY-152292 | Zidesamtinib | Inhibitor | 99.78% | Phase 2 |
| HY-15514 | Merestinib | Inhibitor | 99.99% | Phase 2 |
| HY-15514A | Merestinib dihydrochloride | Inhibitor | 99.36% | Phase 2 |
| HY-155163 | APG-2449 | Inhibitor | 98.93% | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(55)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-N0578 | Apigenin 7-glucoside | 98.98% | Unkown | |
| HY-W015913S | Pyruvic acid-13C3 sodium | Inhibitor | 99.7% | Unkown |
| HY-122311 | Orniplabin | Inhibitor | 98% | Unkown |
| HY-159147 | SIAIS039 | 99.68% | Unkown | |
| HY-12678S1 | Entrectinib-d8 | 99.82% | Unkown | |
| HY-N7798 | Pennogenin | 99.90% | Unkown | |
| HY-50878S | Crizotinib-d5 | 99.60% | Unkown | |
| HY-B1106 | Tetrahydroxyquinone | 98.0% | Unkown | |
| HY-112801 | F-1 | Inhibitor | 98.03% | Unkown |
| HY-12678S | Entrectinib-d4 | Inhibitor | / | Unkown |
| HY-B1106A | Tetrahydroxyquinone monohydrate | 97.0% | Unkown | |
| HY-N10144 | Shinpterocarpin | Inhibitor | / | Unkown |
| HY-N1306 | Sideroxylin | / | Unkown | |
| HY-N2693 | 6,8-Diprenylorobol | 98.40% | Unkown | |
| HY-W015913R | Pyruvic acid sodium (Standard) | Inhibitor | 99.98% | Unkown |
| HY-161358 | FAK-IN-20 | / | Unkown | |
| HY-111416 | WY-135 | Inhibitor | / | Unkown |
| HY-135509 | Lorlatinib acetate | / | Unkown | |
| HY-115541 | BRD4-IN-41 | Inhibitor | / | Unkown |
| HY-117420 | CM764 | Activator | / | Unkown |
| HY-120387 | SMU-B | Inhibitor | / | Unkown |
| HY-122311A | Bis(2R,3R)-Orniplabin | 95.0% | Unkown | |
| HY-123454 | SKF1 | / | Unkown | |
| HY-130794 | ALK/ROS1-IN-1 | Inhibitor | / | Unkown |
| HY-144697 | p38 MAPK-IN-3 | / | Unkown | |
| HY-147795 | Nampt-IN-8 | / | Unkown | |
| HY-150974 | ROS1-IN-1 | Inhibitor | / | Unkown |
| HY-153743 | Protein kinase inhibitor 4 | Inhibitor | / | Unkown |
| HY-155178 | Antiproliferative agent-34 | Inhibitor | / | Unkown |
| HY-156360 | Xanthine oxidase-IN-12 | Inhibitor | / | Unkown |
| HY-157391 | ALK/ROS1-IN-3 | Inhibitor | / | Unkown |
| HY-157437 | AChE/BChE-IN-16 | Inhibitor | / | Unkown |
| HY-158016 | Antiproliferative agent-49 | / | Unkown | |
| HY-161966 | VEGFR-2-IN-52 | / | Unkown | |
| HY-161975 | ROS1-IN-2 | Inhibitor | / | Unkown |
| HY-162311 | Anticancer agent 194 | / | Unkown | |
| HY-163862 | PPARα agonist 3 | / | Unkown | |
| HY-170418 | ALK/ROS1-IN-5 | / | Unkown | |
| HY-178391 | SMU-037 | / | Unkown | |
| HY-179052 | Apoptosis inducer 50 | / | Unkown | |
| HY-179527 | LIG48 | Inhibitor | / | Unkown |
| HY-50878AS | Crizotinib-d9 hydrochloride | / | Unkown | |
| HY-N11887 | Linocinnamarin | Inhibitor | 99.14% | Unkown |
| HY-RS12135 | ROS1 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS12136 | Ros1 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS12137 | ROS1 Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-160172 | ALK/ROS1-IN-4 | Inhibitor | / | Unkown |
| HY-160172A | ALK/ROS1-IN-4 hydrate | Inhibitor | / | Unkown |
| HY-162488 | Laccase-IN-3 | Inhibitor | / | Unkown |
| HY-179710 | SET-12 | / | Unkown | |
| HY-50878S1 | Crizotinib-d8 | / | Unkown | |
| HY-50878S2 | Crizotinib-d9 | / | Unkown | |
| HY-B0847S | Propiconazole-d7 | / | Unkown | |
| HY-W587743 | N1-Acetyl-5-methoxykynuramine hydrochloride | Inhibitor | / | Unkown |
| HY-W927359 | Fluorescein hydrazide (3,6-Dihydroxyxanthane) | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service